Citations

Inflammation is a hallmark of aging and a likely contributor to skeletal muscle loss ( sarcopenia ). We investigated whether the inflammatory phenotype of differentiated primary skeletal muscle‐derived cells (SkMDCs) from a 17‐year‐old (young) differed from that of a 68‐year‐old (older) donor. Under basal conditions, expression of genes encoding pro‐inflammatory cytokines was in fact lower in older compared to younger SkMDCs. However, in response to lipopolysaccharide (LPS), these factors were more highly upregulated in older cells. Specifically, in young compared to older SkMDCs, interleukin‐6 (IL‐6) increased 3‐ vs. 9‐fold, tumor necrosis factor‐alpha (TNF‐alpha) increased 11‐ vs. 80‐fold, and IL‐1alpha increased 14‐ vs. 21‐fold (all differences were p < 0.01). Given adipose tissue is a primary source of pro‐inflammatory stimuli and infiltrates skeletal muscle with age, we hypothesized that secreted factors from senescent preadipocytes drive a similar molecular phenotype to LPS. Exposure of SkMDCs to conditioned medium from senescent‐preadipocytes increased expression IL‐6 and TNF‐alpha in young and even more so in older cells (both p < 0.05). Thus, there are inherent differences in the molecular inflammatory phenotype and its response between young and older SkMDCs. These data also suggest that the age‐related accumulation of senescent preadipocytes may contribute to sarcopenia.

Infiltration of fat cells into skeletal muscle is a hallmark of aging that has been associated with insulin resistance and the pathogenesis of type 2 diabetes mellitus (T2DM). The mechanisms by which fat cells affect the health and metabolic state of skeletal muscle are poorly understood. Given the evidence for cross‐talk between these tissues and the secretory phenotype of senescent preadipocytes, we first utilized real time‐PCR to examine the expression of inflammatory cytokines in primary human skeletal muscle‐derived cells (SkMDCs) in response to conditioned medium (CM) from either control human preadipocytes (Normal CM) or from human preadipocytes driven to senescence by irradiation (Senescent CM). Exposure of SkMDCs to either Normal CM or Senescent CM for 24 hours significantly increased their expression of IL‐6 (5.1±1.7‐and 14.1±4.7‐fold, respectively), TNFα (1.3±0.2‐and 2.1±0.67‐fold, respectively) and MCP‐1 (2.9±1.1‐and 6.8±2.3‐fold, respectively). Next, we investigated the effects of CM on insulin signaling in SkMDCs via Western blot analysis. Exposure of SKMDCs to preadipocyte CM significantly blunted insulin‐stimulated phosphorylation of its downstream effectors, including Akt (14–24%, p<0.05). Finally, we examined the effects of CM on the proliferative capacity of undifferentiated SkMDCs. Senescent CM inhibited SkMDC proliferation by more than 30% (p < 0.05). In conclusion, factors secreted by preadipocytes, and in particular, senescent preadipocytes, negatively impact the inflammatory and metabolic phenotype and the proliferative capacity of skeletal muscle cells. Elucidation of the biologic materials that are secreted from fat cells and mediate these effects may lead to novel therapeutic strategies for the treatment of age‐related conditions, including T2DM. The authors acknowledge the support of Mayo Clinic and a generous gift from Robert and Arlene Kogod.

Significance Statement Renal artery stenosis (RAS) engenders stenotic-kidney ischemia, dysfunction, and injury, but whether these are mediated by cellular senescence has not been elucidated. INK-ATTAC transgenic mice, high-resolution imaging, and unbiased single-cell RNA sequencing of murine kidneys demonstrated cellular senescence as an important mechanism of progressive injury to epithelial/stromal cells within poststenotic kidneys. Both p16-specific and broad quercetin/dasatinib interventions to blunt senescence improved renal function and structure, underscoring the central role of senescence in the pathogenesis. Furthermore, this mechanism was conserved in human subjects with RAS. These observations reveal new mechanisms that contribute to the pathogenesis of chronic ischemic renal injury, and support the development of senolytic therapy to reduce senescent cell burden and delay renal injury. Background Peripheral vascular diseases may induce chronic ischemia and cellular injury distal to the arterial obstruction. Cellular senescence involves proliferation arrest in response to stress, which can damage neighboring cells. Renal artery stenosis (RAS) induces stenotic-kidney dysfunction and injury, but whether these arise from cellular senescenceand their temporal pattern remain unknown. Methods Chronic renal ischemia was induced in transgenic INK-ATTAC and wild type C57BL/6 mice by unilateral RAS, and kidney function ( in vivo micro-MRI) and tissue damage were assessed. Mouse healthy and stenotic kidneys were analyzed using unbiased single-cell RNA-sequencing. To demonstrate translational relevance, cellular senescence was studied in human stenotic kidneys. Results Using intraperitoneal AP20187 injections starting 1, 2, or 4 weeks after RAS, selective clearance of cells highly expressing p16 Ink4a attenuated cellular senescence and improved stenotic-kidney function; however, starting treatment immediately after RAS induction was unsuccessful. Broader clearance of senescent cells, using the oral senolytic combination dasatinib and quercetin, in C57BL/6 RAS mice was more effective in clearing cells positive for p21 ( Cdkn1a ) and alleviating renal dysfunction and damage. Unbiased, single-cell RNA sequencing in freshly dissociated cells from healthy and stenotic mouse kidneys identified stenotic-kidney epithelial cells undergoing both mesenchymal transition and senescence. As in mice, injured human stenotic kidneys exhibited cellular senescence, suggesting this process is conserved. Conclusions Maladaptive tubular cell senescence, involving upregulated p16 ( Cdkn2a ), p19 ( Cdkn2d ), and p21 ( Cdkn1a ) expression, is associated with renal dysfunction and injury in chronic ischemia. These findings support development of senolytic strategies to delay chronic ischemic renal injury.

Introduction: Senescent cells with essentially irreversible loss of replicative potential accumulate in various tissues with aging. Cellular senescence is associated with a pro‐inflammatory senescence‐associated secretory phenotype which the Janus‐associated kinase (JAK) pathway plays a role in. We hypothesized that senescent preadipocytes contribute to age‐related dysfunction of healthy cells. Methods: Preadipocytes from lean subjects were X‐irradiated to induce senescence. We co‐cultured non‐senescent cells with senescent cells or cultured them in conditioned medium (CM) from senescent preadipocytes to test the inflammation, differentiation and insulin sensitivity. Macrophage migration in response to CM was assayed as well. Moreover, we treated old or obese mice with Ruxolitinib, a JAK1/2 inhibitor, to test the beneficial effect. Results: The adipogenesis of preadipocytes was impaired by exposure to senescent cells. Macrophage migration was greater in response to senescent preadipocytes. Inflammation was increased in both adipose tissue and preadipocytes exposed to CM from senescent cells. All these adverse effect could be partially rescued by JAK inhibitor. In addition, senescent preadipocytes inhibited insulin‐induced phosphor‐AKT in adipose tissue and HepG2 cells. Insulin‐induced glycogen synthesis was also inhibited in HepG2 cells. Two months of Ruxolitinib treatment reduced inflammation, reversed age‐related lipodystrophy and improved physical function in frail, 24 month old mice. It also improved insulin sensitivity in diet‐induced obese mice. Conclusion: Senescent preadipocytes contribute to age‐related impairment in adipogenesis, fat tissue inflammation, and insulin resistance. Grant Funding Source : supported by NIH AG13925 and Robert and Arlene Kogod Center on Aging in Mayo Clinic.

Nutrient excess and physical inactivity are primary drivers of numerous age‐related chronic diseases. A growing body of evidence has implicated cellular senescence, a process in which cells lose the ability to divide and concurrently damage neighboring cells by the factors they secrete, as an underlying mechanism of aging and its associated conditions. However, the impact of lifestyle choices on the age‐associated accumulation of senescent cells remains poorly understood. Thus, we examined the effects of a fast food diet (FFD) and a voluntary exercise intervention on multiple parameters of healthspan and cellular senescence using a transgenic mouse model that expresses green fluorescent protein (GFP) in p16 Ink4a ‐positive senescent cells. As expected, 12‐month old male mice that had received the FFD diet for 5 months demonstrated significantly greater gains in body weight and fat mass compared to mice fed a standard chow diet. Moreover, mice fed the FFD exhibited hyperinsulinemia, impaired glucose tolerance, reduced exercise capacity, and diastolic dysfunction. Impressively, providing an exercise wheel (26.9 ± 6.9 km/wk) in parallel with the FFD nullified the deleterious effects of the FFD on body weight and composition, whole‐body metabolism, physical performance and cardiac function. Strikingly, our data further suggest that exercise markedly lowers the number of cells in visceral fat depots that express GFP and stain positively for senescent‐associated β‐galactosidase; markers of senescence, that are highly abundant in sedentary mice fed the FFD. Correspondingly, FFD‐induced expression of senescence‐associated inflammatory factors was also diminished by the exercise intervention. Collectively, our data suggest that lifestyle choices may affect the abundance of senescence cells with advancing age, and exercise may partly mediate its salutary effects on multiple organ systems by preventing their accumulation and/or mediating their removal.

AbstractObjectiveAdipose tissue (AT) senescence is associated with AT dysfunction in rodents, but little is known about human AT senescence. The study goal was to define the distribution of senescent cells in two subcutaneous depots and understand relationships with adiposity and inflammation.MethodsSixty‐three volunteers (48 females) underwent abdominal and femoral subcutaneous fat biopsies. Fat cell size, senescent cells using senescence‐associated β‐galactosidase staining per 100 nucleated cells (percentage), and mRNA expression of four cytokines were measured.ResultsThere was a larger proportion of senescent cells in femoral than abdominal subcutaneous AT (mean difference 1.6% [95% CI: 0.98%‐2.3%], p < 0.001), and the percentage of femoral AT senescent cells was greater in women than men (median 3.9% vs. 2.1%, p < 0.01). There was a positive correlation between senescence and fat cell size in abdominal (rs = 0.44, p < 0.001) and femoral (rs = 0.35, p = 0.007) AT depots. Abdominal AT tumor necrosis factor alpha (rs = 0.49, p < 0.01) and interleukin‐1β (rs = 0.44, p = 0.01) expression was positively correlated with abdominal, but not femoral, AT senescence.ConclusionsIn human subcutaneous AT, there are more senescent cells in femoral than abdominal depots; abdominal AT senescent cells are more associated with inflammatory signals than femoral AT senescent cells.

Senescent cells exacerbate COVID-19 Cellular senescence is a state elicited in response to stress signals and is associated with a damaging secretory phenotype. The number of senescent cells increases with advanced age and this in turn drives age-related diseases. Camell et al. show that senescent cells have an amplified inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see the Perspective by Cox and Lord). This response is communicated to nonsenescent cells, suppressing viral defense mechanisms and increasing the expression of viral entry proteins. In old mice infected with a SARS-CoV-2–related virus, treatment with senolytics to reduce the senolytic cell burden reduced mortality and increased antiviral antibodies. Science , abe4832, this issue p. eabe4832 ; see also abi4474, p. 281

Mesenchymal stem/stromal cells (MSCs) facilitate repair in experimental diabetic kidney disease (DKD). However, the hyperglycemic and uremic milieu may diminish regenerative capacity of patient-derived therapy. We hypothesized that DKD reduces human MSC paracrine function. Adipose-derived MSC from 38 participants with DKD and 16 control subjects were assessed for cell surface markers, trilineage differentiation, RNA sequencing (RNA-seq), in vitro function (coculture or conditioned medium experiments with T cells and human kidney cells [HK-2]), secretome profile, and cellular senescence abundance. The direction of association between MSC function and patient characteristics were also tested. RNA-seq analysis identified 353 differentially expressed genes and downregulation of several immunomodulatory genes/pathways in DKD-MSC versus Control-MSC. DKD-MSC phenotype, differentiation, and tube formation capacity were preserved, but migration was reduced. DKD-MSC with and without interferon-γ priming inhibited T-cell proliferation greater than Control-MSC. DKD-MSC medium contained higher levels of anti-inflammatory cytokines (indoleamine 2,3-deoxygenase 1 and prostaglandin-E2) and prorepair factors (hepatocyte growth factor and stromal cell–derived factor 1) but lower IL-6 versus control-MSC medium. DKD-MSC medium protected high glucose plus transforming growth factor-β–exposed HK-2 cells by reducing apoptotic, fibrotic, and inflammatory marker expression. Few DKD-MSC functions were affected by patient characteristics, including age, sex, BMI, hemoglobin A1c, kidney function, and urine albumin excretion. However, senescence-associated β-galactosidase activity was lower in DKD-MSC from participants on metformin therapy. Therefore, while DKD altered the transcriptome and migratory function of culture-expanded MSCs, DKD-MSC functionality, trophic factor secretion, and immunomodulatory activities contributing to repair remained intact. These observations support testing of patient-derived MSC therapy and may inform preconditioning regimens in DKD clinical trials.

Key points Critical illness myopathy (CIM) is a frequently observed negative consequence of modern critical care. Chronic Janus kinase (JAK)/signal transducer and activator of transcription activation impairs muscle size and function and is prominent following mechanical ventilation. We identify pSTAT‐3 activation in tibialis anterior of CIM patients, before examining the potential benefits of JAK1/2 inhibition in an experimental model of CIM, where muscle mass and function are impaired. CIM activates complement cascade and increased monocyte infiltration in the soleus muscle, which was ameliorated by JAK1/2 inhibition, leading to reduced muscle degeneration and improved muscle force. Here, we demonstrate that JAK1/2 inhibition augments CIM muscle function through regulation of the complement cascade. AbstractCritical illness myopathy (CIM) is frequently observed in response to modern critical care with negative consequences for patient quality of life, morbidity, mortality and healthcare costs. Janus kinase (JAK)/signal transducer and activator of transcription (STAT) activation is observed in limb muscles following controlled mechanical ventilation. Chronic JAK/STAT activation promotes loss of muscle mass and function. Thus, we hypothesized that JAK1/2 inhibition would improve muscle outcomes for CIM. Following 12 days of intensive care unit conditions, pSTAT‐3 levels increased in tibialis anterior muscle of CIM patients (P = 0.0489). The potential of JAK1/2 inhibition was assessed in an experimental model of CIM, where soleus muscle size and force are impaired. JAK1/2 inhibition restores soleus force (P < 0.0001). CIM activated muscle complement cascade, which was ameliorated by JAK1/2 inhibition (P < 0.05, respectively). Soleus macrophage number corresponded with complement activity, leading to reduced muscle degeneration and augmented muscle function (P < 0.05). Thus, JAK/STAT inhibition improves soleus function by modulating the complement cascade and muscle monocyte infiltration. Collectively, we demonstrate that JAK/STAT inhibition augments muscle function in CIM.

Abstract Therapeutics that target cellular senescence, including novel “senolytic” compounds, hold significant promise for treating or preventing obesity-induced metabolic dysfunction, type 2 diabetes, and the multiple complications of diabetes and obesity. Senolytics selectively clear senescent cells, which accumulate with aging and obesity and represent a fundamental mechanism of aging that contributes to metabolic dysfunction and diabetes pathogenesis. In addition to improving metabolic function, targeting senescent cells holds promise as a preventive strategy to reduce the incidence and severity of diabetes complications. The intermittent administration schedule used for senolytic therapy may confer benefits in terms of improving adherence and limiting adverse effects. It is necessary to design effective clinical trials that will safely translate discoveries from preclinical models into human studies that may pave the way for a novel therapeutic class for treating obesity, diabetes, and their complications. In this review, we outline what is known regarding the role of cellular senescence in the pathogenesis of type 2 diabetes and its complications, present evidence from preclinical models that targeting cellular senescence is beneficial, review senolytic drugs, and outline the features of clinical trials investigating the role of targeting senescent cells for diabetes.